Approval · Notice of Compliance 25152 · 2021
COPAXONE: Notice of Compliance 25152
Issued February 4, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25152
- Date
- February 4, 2021
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of 40 mg/ml pre-filled pen
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COPAXONE | 02512173 | Approved |
Medicinal ingredients
- GLATIRAMER ACETATE 40 MG per ML